AbbVie Inc. (ABBV) Stock Price, News, Analysis

Technical Score (1D)

SELL

News Sentiment

BULLISH

What’s happening to ABBV today?

AbbVie Inc. is successfully navigating the transition away from Humira, with its immunology drugs Skyrizi and Rinvoq showing substantial growth. These newer therapies are projected to surpass Humira's peak sales, indicating a strong diversification strategy into immunology and oncology. This ongoing revenue expansion in new therapeutic areas is crucial for offsetting the impact of Humira's patent expirations. Investors will want to watch the continued uptake and market penetration of Skyrizi and Rinvoq as they become the primary growth drivers for the company.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

AbbVie Inc. (ABBV) is successfully managing the transition away from its former blockbuster drug, Humira. The company's immunology drugs, Skyrizi and Rinvoq, are demonstrating significant growth, with combined sales reaching $6.9 billion and projected to exceed Humira's peak performance. This diversification into new therapies in immunology and oncology is offsetting the revenue decline from Humira's patent expirations.

What did this article say?

AbbVie (ABBV) shares experienced a decline of 2.52% in the latest trading session, underperforming the broader market indices. This recent dip follows a month where the stock has also seen a slight decrease, though it has outperformed the medical sector. Upcoming earnings are anticipated to show significant year-over-year growth in both EPS and revenue, with analysts revising estimates upwards, suggesting a positive outlook on the company's financial health.

What did this article say?

AbbVie's stock experienced a minor decline, trading down 1% on Thursday with a slight increase in trading volume. Recent developments include positive progress in a risankizumab dosing study and promising Phase 1 results for ABBV-295, both bolstering the company's immunology pipeline. Additionally, RBC Capital initiated coverage with an Outperform rating and a $260 target, citing confidence in Skyrizi and Rinvoq growth.

What did this article say?

This article compares Ironwood Pharmaceuticals (IRWD) and Puma Biotechnology (PBYI) as investment opportunities, highlighting their reliance on single key drugs. ABBV is mentioned as a collaborator with Ironwood on Linzess, a gastrointestinal disorder drug, sharing profits and losses. The analysis aims to determine which small-cap biotech presents a better investment case.

What did this article say?

UCB's Bimzelx demonstrated superiority over AbbVie's Skyrizi in a Phase III psoriatic arthritis study, meeting its primary endpoint for ACR50 response. Despite the positive readout for Bimzelx, analysts remain skeptical about a significant impact on Skyrizi's market uptake or sales. Further data on secondary endpoints are pending.

What did this article say?

RBC Capital initiated coverage on AbbVie (ABBV) with an Outperform rating and a $260 price target, asserting the company's growth story is in its early stages. The firm highlights that investors are underestimating long-term expansion potential, particularly as Skyrizi and Rinvoq sales gain traction. RBC points to AbbVie's strong earnings-per-share growth of approximately 17%, significantly outpacing competitors, and notes its valuation is attractive relative to peers facing patent cliffs.

What did this article say?

AbbVie reported positive Phase 1 data for ABBV-295, a long-acting amylin analog targeting obesity. The study demonstrated significant weight loss across various dosing frequencies in adult participants, with weekly dosing achieving up to a 9.79% reduction by week 12. The drug was generally well-tolerated at all tested dose levels, suggesting potential for future development in the weight management space.

What did this article say?

AbbVie's fair value estimate has seen a minor adjustment, reflecting a divided analyst outlook. Some analysts are optimistic about immunology growth and pipeline advancements, while others highlight competitive pressures and a more balanced risk-reward profile. This divergence shapes the ongoing narrative for the company.

What did this article say?

The bipolar depression market is projected for accelerated growth between 2026 and 2036, driven by advancements in psychiatric therapies. Key pipeline drugs from companies including AbbVie, Xenon Pharmaceuticals, and Autobahn Therapeutics are expected to contribute to this expansion. Increased healthcare spending across major markets is also a significant factor.

What did this article say?

UCB's Bimzelx demonstrated superiority over an IL-23 blocker in a psoriatic arthritis trial, marking a first for approved biologics. While this presents a competitive challenge, analysts remain uncertain about the commercial impact of these findings. Investors should monitor how this head-to-head data influences market share dynamics and future treatment guidelines.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

ABBV·AbbVie Inc.

What’s happening to ABBV today?

Recent News Coverage

Recent News Coverage